Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana

ilustraciones, tablas

Autores:
Prieto Rayo, Yised Natalia
Tipo de recurso:
Fecha de publicación:
2021
Institución:
Universidad Nacional de Colombia
Repositorio:
Universidad Nacional de Colombia
Idioma:
spa
OAI Identifier:
oai:repositorio.unal.edu.co:unal/80045
Acceso en línea:
https://repositorio.unal.edu.co/handle/unal/80045
https://repositorio.unal.edu.co/
Palabra clave:
610 - Medicina y salud::616 - Enfermedades
Rheumatoid arthritis
Artritis reumatoide
Remisión sostenida
Artritis reumatoide temprana
Factores pronósticos
Remisión sostenida
Remisión
Early rheumatoid arthritis
Predicting factors
Remission
Sustained
Rights
openAccess
License
Atribución-NoComercial-SinDerivadas 4.0 Internacional
id UNACIONAL2_3e4c385cf9846740ccc2ce2c61284238
oai_identifier_str oai:repositorio.unal.edu.co:unal/80045
network_acronym_str UNACIONAL2
network_name_str Universidad Nacional de Colombia
repository_id_str
dc.title.none.fl_str_mv Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
dc.title.translated.none.fl_str_mv Predictive factors of clinical activity in a patient with early rheumatoid arthritis in a Colombian cohort
title Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
spellingShingle Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
610 - Medicina y salud::616 - Enfermedades
Rheumatoid arthritis
Artritis reumatoide
Remisión sostenida
Artritis reumatoide temprana
Factores pronósticos
Remisión sostenida
Remisión
Early rheumatoid arthritis
Predicting factors
Remission
Sustained
title_short Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
title_full Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
title_fullStr Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
title_full_unstemmed Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
title_sort Factores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana
dc.creator.fl_str_mv Prieto Rayo, Yised Natalia
dc.contributor.advisor.none.fl_str_mv Quintana-Lopez, Gerardo
dc.contributor.author.none.fl_str_mv Prieto Rayo, Yised Natalia
dc.subject.ddc.spa.fl_str_mv 610 - Medicina y salud::616 - Enfermedades
topic 610 - Medicina y salud::616 - Enfermedades
Rheumatoid arthritis
Artritis reumatoide
Remisión sostenida
Artritis reumatoide temprana
Factores pronósticos
Remisión sostenida
Remisión
Early rheumatoid arthritis
Predicting factors
Remission
Sustained
dc.subject.lemb.none.fl_str_mv Rheumatoid arthritis
Artritis reumatoide
dc.subject.proposal.none.fl_str_mv Remisión sostenida
dc.subject.proposal.spa.fl_str_mv Artritis reumatoide temprana
Factores pronósticos
Remisión sostenida
Remisión
dc.subject.proposal.eng.fl_str_mv Early rheumatoid arthritis
Predicting factors
Remission
Sustained
description ilustraciones, tablas
publishDate 2021
dc.date.accessioned.none.fl_str_mv 2021-08-27T21:24:09Z
dc.date.available.none.fl_str_mv 2021-08-27T21:24:09Z
dc.date.issued.none.fl_str_mv 2021-08-26
dc.type.spa.fl_str_mv Trabajo de grado - Especialidad Médica
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.content.spa.fl_str_mv Text
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/TM
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unal.edu.co/handle/unal/80045
dc.identifier.instname.spa.fl_str_mv Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv https://repositorio.unal.edu.co/
url https://repositorio.unal.edu.co/handle/unal/80045
https://repositorio.unal.edu.co/
identifier_str_mv Universidad Nacional de Colombia
Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis : pathological mechanisms and modern pharmacologic therapies. Bone Res [Internet]. 2018;(87). Available from: http://dx.doi.org/10.1038/s41413-018-0016-9
2. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Best Practice & Research Clinical Rheumatology Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol [Internet]. 2017;1–16. Available from: http://dx.doi.org/10.1016/j.berh.2017.08.003
3. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol 2016;12(6):335e43
4. Carmona L, Ot T. Best Practice & Research Clinical Rheumatology The epidemiology of established rheumatoid arthritis. 2019;(xxxx).
5. Tobón GJ, Youinou P, Saraux A. The environment , geo-epidemiology , and autoimmune disease : Rheumatoid arthritis. J Autoimmun [Internet]. 2010;35(1):10–4. Available from: http://dx.doi.org/10.1016/j.jaut.2009.12.009
6. Fernández-ávila DG, Rincón-ria DN, Gutiérrez JM. Investigación original Prevalencia de la artritis reumatoide en Colombia según información del Sistema Integral de Información de la Protección Social. 2020;6(2):83–7.
7. Machado-alba JE, Felipe A, Alejandro D, Morales M. The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol [Internet]. 2015;22(3):148–52. Available from: http://dx.doi.org/10.1016/j.rcreu.2015.05.006
8. Díaz-rojas JA, Dávila-ramírez FA, Quintana-lópez G, Aristizábal-gutiérrez F. Investigación original Prevalencia de artritis reumatoide en Colombia : una aproximación basada en la carga de la enfermedad durante el a no. Rev Colomb Reumatol [Internet]. 2016;(x x):2–7. Available from: http://dx.doi.org/10.1016/j.rcreu.2015.12.004
9. Silman AJ, Hennessy E, Ollier B (1992) Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol31(6):365–368
10. Adi J. Insights of rheumatoid arthritis risk factors and associations. J Transl Autoimmun [Internet]. 2019;2(March):100012. Available from: https://doi.org/10.1016/j.jtauto.2019.100012
11. Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis Katherine P. 2009
12. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking Intensity , Duration , and Cessation , and the Risk of Rheumatoid Arthritis in Women. 2006;503–11.
13. Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis Katherine P. 2009
14. Azizov V, Dietel K, Steffen F, Dürholz K, Meidenbauer J, Lucas S, et al. and the development of autoimmune arthritis. Nat Commun [Internet]. (2020). Available from: http://dx.doi.org/10.1038/s41467-020-15855-z
15. Manuscript A. NIH Public Access. 2013;45(2):170–9.
16. Yarwood A, Huizinga TWJ, Worthington J. RA : from risk factors and pathogenesis to prevention The genetics of rheumatoid arthritis : risk and protection in different stages of the evolution of RA. 2016;(September 2014):199–209.
17. Viatte S. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. 2017;395–408.
18. Castro-santos P, Díaz-pe R. Review article Genetics of rheumatoid arthritis: a new boost is. 2015;6(2):171–7.
19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Arthritis & Rheumatism. 2010;62(9):2569–81.
20. Zambon A, Caporali R, Sakellariou G, Scire CA, Montecucco C. Performance of the 2010 Classification Criteria for Rheumatoid Arthritis : A Systematic Literature Review and a Meta-Analysis. 2013;8(2):1–10.
21. Jeffery RC. Clinical features of rheumatoid arthritis. Medicine (Baltimore) [Internet]. 2014;42(5):231–6. Available from: http://dx.doi.org/10.1016/j.mpmed.2014.02.011
22. Grassi W, Angelis R De, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. 1998;27:18–24.
23. Lee DM, Weinblatt ME. Rheumatoid arthritis. 2001;358:903–11.
24. Nell V, Stamm T, Aletaha D, Smolen JS. Early rheumatoid arthritis. :282–8
. 25. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-gracia JM, et al. 2016 update of the EUL AR recommendations for the management of early arthritis. 2017;948–59.
26. Cannella AC, Dell JRO. Early Rheumatoid Arthritis Pitfalls in Diagnosis and Review of Recent Clinical Trials. 2006;66(10):1319–37.
27. Kmiliauskis R, Gomes S, Linhares AC De, Lersch LS. Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil. 2018;8:1–10.
28. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis ? 2018;0.
29. Wabe N, Wojciechowski J, Wechalekar MD, Cleland LG, Mcwilliams L, Lee A, et al. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years : association with persistence to therapy. 2017;
30. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7- year study from the Oslo RA register. Scand J Rheumatol 2005;6:441–7.
31. Twigg S, Hensor EMA, Emery P, Tennant A, Morgan AW, Twigg S, et al. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis : Results from the Yorkshire Early Arthritis Register Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis : Results from the Yorkshire Early Arthritis Register. 2017
32. Forslind K, Hafstro I. Sex : a major predictor of remission in early rheumatoid. 2007;46–53.
33. Bird P, Nicholls D, Barrett R, Jager JDE, Griffiths H, Roberts L, et al. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis : the PREDICT study. 2017;1–9.
34. Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and Management of Rheumatoid Arthritis. 2018
35. Gremese E, Salaf F, Bosello SL, Ciapetti A, Bobbio-pallavicini F, Caporali R, et al. Very early rheumatoid arthritis as a predictor of remission : a multicentre real life prospective study. 2013;(July 2009):858–62.
36. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B. Very early rheumatoid arthritis is the major predictor of major outcomes : clinical ACR remission and radiographic non-progression. 2011;1292–5.
37. Sundlisæter NP, Olsen IC, Aga A, Heijde V Der, Kvien TK, Hammer B, et al. Original article Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. 2018;(July):1–10.
38. Maxwell JR, Gowers IR, Moore DJ, Wilson AG. Original article Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. 2010;(July):2140–6.
39. Pedersen M, Jacobsen S, Klarlund M, Pedersen B V, Wiik A, Wohlfahrt J, et al. Research article Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. 2006;8(4).
40. Hazes W, Dijkmans AC, Vandenbroucke P. Lifestyle and the risk of rheumatoid arthritis : cigarette smoking and alcohol consumption. 1990;980–2.
41. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010; 69(1):70–81. [PubMed: 19174392]
42. Sparks JA, Chang S, Nguyen UDT, Costenbader H, Zhang Y, Choi HK. HHS Public Access. 2019;70(1):19–29.
43. Rydell E, Forslind K, Nilsson J-åke, Jacobsson LTH, Turesson C. Smoking , body mass index , disease activity , and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. 2018;1–11.
44. Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Albertsson K, Forslind K, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis : results from the SWEFOT trial. 2015;1509–14.
45. Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Health technology assessment. 2018;22(66).
46. Zeben D Van, Hazes JMW, Zwinderman AH, Cats A. Clinical significance of rheumatoid factors in early rheumatoid arthritis : results of a follow up study. 1992;1029–35.
47. Eberhardt K, Hafstro I. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). 2004;1090–5.
48. Report E. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). 2004;1085–9.
49. of low titer anti-nuclear antibodies in early rheumatoid arthritis : implications on the presentation and long-term course of the disease. 2001;43–7.
50. Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, et al. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis response to biological disease-modifying anti-rheumatic drugs in patients. Semin Arthritis Rheum [Internet]. 2019;(February). Available from: https://doi.org/10.1016/j.semarthrit.2019.02.003
51. High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent-Onset Rheumatoid Arthritis. 2013;65(8):1235–42.
52. he Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis, DOI 10.1002/acr.22932
53. Boire G, Mph JEP, Hitchon C. No Title. :0–3. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study. 2016.
54. Activity D, Damage J. HHS Public Access. 2016;67(7):940–6.
55. Yang G, Bykerk VP, Boire G, Hitchon CA, Thorne JC, Tin D, et al. Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. 2015;
56. Yang D, Huang J, Chiou J, Wei JC. Analysis of Socioeconomic Status in the Patients with Rheumatoid Arthritis. 2018;
57. Massardo L, Pons-estel BA, Wojdyla D, Cardiel MH, Sacnun NP, Soriano ER, et al. Early Rheumatoid Arthritis in Latin America: Low Socioeconomic Status Related to High Disease Activity at Baseline. 2012;64(8):1135–43.
58. Smolen JS, Heijde MFM Van Der, Clair EWS, Emery P, Bathon JM, Keystone E, et al. Predictors of Joint Damage in Patients With Early Rheumatoid Arthritis Treated With High-Dose Methotrexate With or Without Concomitant Infliximab Results From the ASPIRE Trial. 2006;54(3):702–10.
59. Salaffi F. R eview Clinical disease activity assessments in rheumatoid arthritis R eview. 2013;347–60.
60. Prevoo MLL, Hof MAVANT, Kuper HH, Leeuwen MAVAN. MODIFIED DISEASE ACTIVITY SCORES THAT INCLUDE TWENTY-EIGHT-JOINT COUNTS Development and Validation in a Prospective Longitudinal Study of Patients with Rheumatoid Arthritis. 1995;38(1):44–8.
61. Singh H, Kumar H, Handa R, Talapatra P, Ray S, Gupta V. Use of Clinical Disease Activity Index Score for Assessment of Disease Activity in Rheumatoid Arthritis Patients : An Indian Experience. 2011;2011.
62. Assessment MH, Health I, Questionnaire A. Measures of Functional Status and Quality of Life in Rheumatoid Arthritis. 2011;63(November):4–13.
63. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the Health Assessment Questionnaire ( HAQ ) and the modified HAQ ( MHAQ ) in patients with rheumatoid arthritis. 2006;(454):454–8
64. Subramanian S. Remission in Rheumatoid arthritis: a reality in 2017. 2017;(January).
65. Felson D. (2012). Defining remission in rheumatoid arthritis. Annals of the rheumatic diseases, 71 Suppl 2(0 2), i86–i88. https://doi.org/10.1136/annrheumdis
66. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis : latest evidence and clinical considerations. 2017;249–62.
67. Id YS, Yoshida K, Prince FHM, Frits ML, Cho K, Choe J, et al. Prevalence and predictors for sustained remission in rheumatoid arthritis. 2019;92:1–11.
68. Yilmaz-oner S, Gazel U, Can M, Atagunduz P, Direskeneli H, Inanc N. Predictors and the optimal duration of sustained remission in rheumatoid arthritis. 2019;
69. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. 2017;1–18.
70. Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. 2019; 4:1–16.
71. Peláez I, Cuervo F, Angarita I, Londo J, Giraldo R, Camilo J, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación prevalencia de enfermedad reumática en población colombiana mayor de 18 a nos. 2018;5(4):245–56.
72. Montoya N, Rosselli D. Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia. 2011; 18:26–33.
73. Kiely P, Williams R, Walsh D, Young A, Arthritis R, Eran N. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis : the ERAN cohort. 2009;(November 2008):57–60.
74. Brian Tom , Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study RA-MAP Consortium, medRxiv 2020.03.08.20028142
75. .Combe B. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. 2004;675–80.
76. 1Boire G, Mph JEP, Hitchon C. 1. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study
77. Thorne C, Bykerk V, Lazovskis J, Breton C, Hospital R. The Journal of Rheumatology Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists : A National , Multicenter , Retrospective Cohort. 2011;(April 2016).
78. Boman A, Brink M, Lundquist A, Hansson M, Mathsson-alm L, Rönnelid J, et al. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis : a prospective longitudinal inception cohort study. 2019;1–10.
79. Rydell E, Forslind K, Nilsson J-åke, Karlsson M, Åkesson KE, Jacobsson LTH, et al. Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis : a cohort study. 2021;1–13.
80. Hmamouchi I, Combe B, Fautrel B, Rincheval N, Lukas C. validated indices in the early arthritis “ESPOIR ” cohort. Jt Bone Spine [Internet]. 2014; Available from: http://dx.doi.org/10.1016/j.jbspin.2014.02.007
81. Lu B, Rho YH, Cui J, Christine K. Associations of Smoking and Alcohol Consumption With Disease Activity and Functional Status in Rheumatoid Arthritis2015;41(1):24–30.
82. Paulus HE, Wiesner J, Bulpitt KENJ, Patnaik M, Law J, Park GS, et al. Autoantibodies in Early Seropositive Rheumatoid Arthritis , Before and During Disease Modifying Antirheumatic Drug Treatment. 2002;2513–20.
83. Barahona-correa JE, Flórez-suárez J. Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis ? 2020;
84. Ma MHY, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PDW, et al. Remission in Early Rheumatoid Arthritis : Predicting Treatment Response. 2012;39(3)
. 85. Ma MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. 2020;1–12.
86. Källmark H, Einarsson JT, Nilsson Å, Olofsson T, Saxne T, Geborek P. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy : A Swedish Nationwide Register Study. 2021;73(7):1135–44.
87. Turk ,Kieran Murray, Yousef Alammari,1 Aine Gorman,1 Francis Young,1 Phil Gallagher, The effects of alcohol consumption and its associations with disease activity among 979 patients with inflammatory arthritis _ Enhanced Reader.pdf.
88. Nissen MJ, Gabay C, Scherer A, Finckh A, Clinical S. The Effect of Alcohol on Radiographic Progression in Rheumatoid Arthritis. 2010;62(5):1265–72.
89. Monteagudo-sa I, Kupper H. Clinical Remission and / or Minimal Disease Activity in Patients Receiving Adalimumab Treatment in a Multinational , Open-Label , Twelve-Week Study. 2008;59(1):32–41.
90. Frisell T, Saevarsdottir S, Askling J. Does a family history of RA in fl uence the clinical presentation and treatment response in RA ? 2015;1–6.
91. Radstake TRDJ, Barrera P, Albers JMC, Swinkels HL, Putte LBA Van De, Riel PLCM Van. Familial vs sporadic rheumatoid arthritis ( RA ). A prospective study in an early RA inception cohort. 2000;267–73.
92. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, et al. Significance of Sex in Achieving Sustained Remission in the Consortium of Rheumatology Researchers of North America Cohort of Rheumatoid Arthritis Patients. 2012;64(12):1811–8.
93. Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, et al. Original article Sustained clinical remission in rheumatoid arthritis : prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. 2012;(November 2011):169–75.
94. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. 2004;43(7):906–14.
95. Anderson JJ, Wells G, Verhoeven AC, Felson DT. FACTORS PREDICTING RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS The Importance of Disease Duration. 2000;43(1):22–9.
96. Ruiz-Esquide, V. Smoking Impact on Radiographic Progression in An Early Rheumatoid Arthritis Cohort, 2011
97. Saevarsdottir S, Wedre S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients With Early Rheumatoid Arthritis Who Smoke Are Less Likely to Respond to Treatment With Methotrexate and Tumor Necrosis Factor Inhibitors Observations From the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register Cohorts. 2011;63(1):26–36.
98. Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis : current status and future studies. 2020;1–9.
99. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–1099.
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 115 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv Bogotá - Medicina - Especialidad en Reumatología
dc.publisher.department.spa.fl_str_mv Departamento de Medicina Interna
dc.publisher.faculty.spa.fl_str_mv Facultad de Medicina
dc.publisher.place.spa.fl_str_mv Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv Universidad Nacional de Colombia - Sede Bogotá
institution Universidad Nacional de Colombia
bitstream.url.fl_str_mv https://repositorio.unal.edu.co/bitstream/unal/80045/1/license.txt
https://repositorio.unal.edu.co/bitstream/unal/80045/2/Factores%20predictores%20de%20actividad%20cl%c3%adnica%20en%20paciente%20con%20artritis%20reumatoide%20temprana%20en%20una%20cohorte%20colombiana.pdf
https://repositorio.unal.edu.co/bitstream/unal/80045/3/Factores%20predictores%20de%20actividad%20cl%c3%adnica%20en%20paciente%20con%20artritis%20reumatoide%20temprana%20en%20una%20cohorte%20colombiana.pdf.jpg
bitstream.checksum.fl_str_mv cccfe52f796b7c63423298c2d3365fc6
34ce8b1f816cb49e6f684e1b87accd36
22df8cdcd40bdca11d7555aa4311b967
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv repositorio_nal@unal.edu.co
_version_ 1814090176557744128
spelling Atribución-NoComercial-SinDerivadas 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Quintana-Lopez, Gerardo18d1f1490a9034eca669599b8a4f4ffd600Prieto Rayo, Yised Natalia50e5714a7f137c310de3cc432dc8e3d62021-08-27T21:24:09Z2021-08-27T21:24:09Z2021-08-26https://repositorio.unal.edu.co/handle/unal/80045Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, tablasMateriales y Métodos: El proyecto se realizó a partir de una cohorte histórica de la Clínica de Artritis Reumatoide de la fundación santa fe de Bogotá, seleccionando pacientes con inicio de los síntomas menores de 12 meses. Buscamos encontrar factores asociados a remisión sostenida a corto plazo definida como DAS28 VSG <2.6, DAS 28 PCR <2.6, SDAI <3.3 CDAI <2.8 en al menos dos ocasiones consecutivas donde el tiempo entre la primera y la última visita en la que la enfermedad estaba en remisión fue ≥ 6 meses o ≥ 24 meses remisión sostenida a largo plazo. Se realizó un análisis univariado y análisis multivariado de Regresión Logística para la selección de variables Resultados: 165 paciente fueron incluidos. Se logro remisión sostenida a corto plazo por DAS 28 VSG en 74% de los pacientes, remisión por DAS 28 PCR en el 50% de los pacientes, remisión sostenida a largo plazo DAS 28 VSG en 46% de los pacientes, DAS 28 PCR en 52% de los pacientes. Los predictores de remisión sostenida a corto plazo fueron Artritis reumatoide muy temprana (OR 2,6 CI 1.26-5.91; P=0.012), Consumo de alcohol (OR 3,86 CI 0.98-18.1 P=0.065), DAS 28 VSG_0 (OR 0.41 CI 0.26-0.62 P=<0.001), Antecedente familiar de AR (OR 0.42 CI 0.17-0.99 P=0.052) y los factores de remisión sostenida a largo plazo fueron el sexo masculino (OR 5.21; CI 1.98-14.9; P=0.001), y la duración de síntomas e inicio de FARME (OR 0.81 CI 0.66-0.99; P=0-046) Conclusiones: Las características demográficas de la cohorte fueron similares a las encontradas en cohortes previamente descritas, los factores que podrían predecir remisión sostenida a corto plazo con significancia estadística fueron el diagnóstico temprano de la enfermedad (VERA), el consumo de alcohol y la menor clinimetria por DAS28 VSG, al ingreso a la cohorte y los factores predictores de remisión sostenida a largo plazo fueron ser hombre y el inicio temprano de terapia.Rheumatoid arthritis is a chronic systemic disease, in which early diagnosis is essential in the prevention of unfavorable outcomes. Materials and methods: This project was elaborated from a historic cohort from the Clínica de Artritis Reumatoide, Fundación Santa Fe de Bogotá, selecting patients with an onset of symptoms lesser than 12 moths. We aim to find associated factors with a short term sustained remission defined by DAS28 VSG <2.6, DAS 28 PCR <2.6, SDAI <3.3 CDAI <2.8 in least in two consecutive locations in between the first and last medical visit, time in which the disease was on remission, ≥ 6 months defined as short term sustained remission or ≥ 24 moths defined as long term sustained remission. A univariate analysis was made, along with a multivariate logistic regression analysis to carry out the selection of the variables. Results: 165 patients were included in the study. Short term sustained remission by DAS 28 VSG was achieved in 74%of the patients, DAS 28 PCR in 50% of the patients, long term sustained remission by DAS 28 VSG in 46% of the patients and DAS 28 PCR in 52% of the patients. The predictors of short term sustained remission were Very Early Rheumatoid Arthritis OR 2,69; (OR 2,6 CI 1.26-5.91; P=0.012), alcohol consumption (OR 3,86 CI 0.98- 18.1 P=0.065), DAS 28 VSG_0 (OR 0.41 CI 0.26-0.62 P=<0.001), and family history of AR (OR 0.42 CI 0.17-0.99 P=0.052). The predictors for long term sustained remission were male gender (OR 5.21; CI 1.98-14.9; P=0.001), duration of the symptoms and the onset of FARME (OR 0.81 CI 0.66-0.99; P=0-046).Especialidades MédicasEspecialista en ReumatologiaEstudio de cohorte histórica115 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Especialidad en ReumatologíaDepartamento de Medicina InternaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::616 - EnfermedadesRheumatoid arthritisArtritis reumatoideRemisión sostenidaArtritis reumatoide tempranaFactores pronósticosRemisión sostenidaRemisiónEarly rheumatoid arthritisPredicting factorsRemissionSustainedFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombianaPredictive factors of clinical activity in a patient with early rheumatoid arthritis in a Colombian cohortTrabajo de grado - Especialidad Médicainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TM1. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis : pathological mechanisms and modern pharmacologic therapies. Bone Res [Internet]. 2018;(87). Available from: http://dx.doi.org/10.1038/s41413-018-0016-92. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Best Practice & Research Clinical Rheumatology Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol [Internet]. 2017;1–16. Available from: http://dx.doi.org/10.1016/j.berh.2017.08.0033. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol 2016;12(6):335e434. Carmona L, Ot T. Best Practice & Research Clinical Rheumatology The epidemiology of established rheumatoid arthritis. 2019;(xxxx).5. Tobón GJ, Youinou P, Saraux A. The environment , geo-epidemiology , and autoimmune disease : Rheumatoid arthritis. J Autoimmun [Internet]. 2010;35(1):10–4. Available from: http://dx.doi.org/10.1016/j.jaut.2009.12.0096. Fernández-ávila DG, Rincón-ria DN, Gutiérrez JM. Investigación original Prevalencia de la artritis reumatoide en Colombia según información del Sistema Integral de Información de la Protección Social. 2020;6(2):83–7.7. Machado-alba JE, Felipe A, Alejandro D, Morales M. The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol [Internet]. 2015;22(3):148–52. Available from: http://dx.doi.org/10.1016/j.rcreu.2015.05.0068. Díaz-rojas JA, Dávila-ramírez FA, Quintana-lópez G, Aristizábal-gutiérrez F. Investigación original Prevalencia de artritis reumatoide en Colombia : una aproximación basada en la carga de la enfermedad durante el a no. Rev Colomb Reumatol [Internet]. 2016;(x x):2–7. Available from: http://dx.doi.org/10.1016/j.rcreu.2015.12.0049. Silman AJ, Hennessy E, Ollier B (1992) Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol31(6):365–36810. Adi J. Insights of rheumatoid arthritis risk factors and associations. J Transl Autoimmun [Internet]. 2019;2(March):100012. Available from: https://doi.org/10.1016/j.jtauto.2019.10001211. Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis Katherine P. 200912. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking Intensity , Duration , and Cessation , and the Risk of Rheumatoid Arthritis in Women. 2006;503–11.13. Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis Katherine P. 200914. Azizov V, Dietel K, Steffen F, Dürholz K, Meidenbauer J, Lucas S, et al. and the development of autoimmune arthritis. Nat Commun [Internet]. (2020). Available from: http://dx.doi.org/10.1038/s41467-020-15855-z15. Manuscript A. NIH Public Access. 2013;45(2):170–9.16. Yarwood A, Huizinga TWJ, Worthington J. RA : from risk factors and pathogenesis to prevention The genetics of rheumatoid arthritis : risk and protection in different stages of the evolution of RA. 2016;(September 2014):199–209.17. Viatte S. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. 2017;395–408.18. Castro-santos P, Díaz-pe R. Review article Genetics of rheumatoid arthritis: a new boost is. 2015;6(2):171–7.19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Arthritis & Rheumatism. 2010;62(9):2569–81.20. Zambon A, Caporali R, Sakellariou G, Scire CA, Montecucco C. Performance of the 2010 Classification Criteria for Rheumatoid Arthritis : A Systematic Literature Review and a Meta-Analysis. 2013;8(2):1–10.21. Jeffery RC. Clinical features of rheumatoid arthritis. Medicine (Baltimore) [Internet]. 2014;42(5):231–6. Available from: http://dx.doi.org/10.1016/j.mpmed.2014.02.01122. Grassi W, Angelis R De, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. 1998;27:18–24.23. Lee DM, Weinblatt ME. Rheumatoid arthritis. 2001;358:903–11.24. Nell V, Stamm T, Aletaha D, Smolen JS. Early rheumatoid arthritis. :282–8. 25. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-gracia JM, et al. 2016 update of the EUL AR recommendations for the management of early arthritis. 2017;948–59.26. Cannella AC, Dell JRO. Early Rheumatoid Arthritis Pitfalls in Diagnosis and Review of Recent Clinical Trials. 2006;66(10):1319–37.27. Kmiliauskis R, Gomes S, Linhares AC De, Lersch LS. Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil. 2018;8:1–10.28. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis ? 2018;0.29. Wabe N, Wojciechowski J, Wechalekar MD, Cleland LG, Mcwilliams L, Lee A, et al. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years : association with persistence to therapy. 2017;30. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7- year study from the Oslo RA register. Scand J Rheumatol 2005;6:441–7.31. Twigg S, Hensor EMA, Emery P, Tennant A, Morgan AW, Twigg S, et al. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis : Results from the Yorkshire Early Arthritis Register Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis : Results from the Yorkshire Early Arthritis Register. 201732. Forslind K, Hafstro I. Sex : a major predictor of remission in early rheumatoid. 2007;46–53.33. Bird P, Nicholls D, Barrett R, Jager JDE, Griffiths H, Roberts L, et al. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis : the PREDICT study. 2017;1–9.34. Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and Management of Rheumatoid Arthritis. 201835. Gremese E, Salaf F, Bosello SL, Ciapetti A, Bobbio-pallavicini F, Caporali R, et al. Very early rheumatoid arthritis as a predictor of remission : a multicentre real life prospective study. 2013;(July 2009):858–62.36. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B. Very early rheumatoid arthritis is the major predictor of major outcomes : clinical ACR remission and radiographic non-progression. 2011;1292–5.37. Sundlisæter NP, Olsen IC, Aga A, Heijde V Der, Kvien TK, Hammer B, et al. Original article Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. 2018;(July):1–10.38. Maxwell JR, Gowers IR, Moore DJ, Wilson AG. Original article Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. 2010;(July):2140–6.39. Pedersen M, Jacobsen S, Klarlund M, Pedersen B V, Wiik A, Wohlfahrt J, et al. Research article Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. 2006;8(4).40. Hazes W, Dijkmans AC, Vandenbroucke P. Lifestyle and the risk of rheumatoid arthritis : cigarette smoking and alcohol consumption. 1990;980–2.41. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010; 69(1):70–81. [PubMed: 19174392]42. Sparks JA, Chang S, Nguyen UDT, Costenbader H, Zhang Y, Choi HK. HHS Public Access. 2019;70(1):19–29.43. Rydell E, Forslind K, Nilsson J-åke, Jacobsson LTH, Turesson C. Smoking , body mass index , disease activity , and the risk of rapid radiographic progression in patients with early rheumatoid arthritis. 2018;1–11.44. Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Albertsson K, Forslind K, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis : results from the SWEFOT trial. 2015;1509–14.45. Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, et al. Health technology assessment. 2018;22(66).46. Zeben D Van, Hazes JMW, Zwinderman AH, Cats A. Clinical significance of rheumatoid factors in early rheumatoid arthritis : results of a follow up study. 1992;1029–35.47. Eberhardt K, Hafstro I. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). 2004;1090–5.48. Report E. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). 2004;1085–9.49. of low titer anti-nuclear antibodies in early rheumatoid arthritis : implications on the presentation and long-term course of the disease. 2001;43–7.50. Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, et al. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis response to biological disease-modifying anti-rheumatic drugs in patients. Semin Arthritis Rheum [Internet]. 2019;(February). Available from: https://doi.org/10.1016/j.semarthrit.2019.02.00351. High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent-Onset Rheumatoid Arthritis. 2013;65(8):1235–42.52. he Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis, DOI 10.1002/acr.2293253. Boire G, Mph JEP, Hitchon C. No Title. :0–3. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study. 2016.54. Activity D, Damage J. HHS Public Access. 2016;67(7):940–6.55. Yang G, Bykerk VP, Boire G, Hitchon CA, Thorne JC, Tin D, et al. Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. 2015;56. Yang D, Huang J, Chiou J, Wei JC. Analysis of Socioeconomic Status in the Patients with Rheumatoid Arthritis. 2018;57. Massardo L, Pons-estel BA, Wojdyla D, Cardiel MH, Sacnun NP, Soriano ER, et al. Early Rheumatoid Arthritis in Latin America: Low Socioeconomic Status Related to High Disease Activity at Baseline. 2012;64(8):1135–43.58. Smolen JS, Heijde MFM Van Der, Clair EWS, Emery P, Bathon JM, Keystone E, et al. Predictors of Joint Damage in Patients With Early Rheumatoid Arthritis Treated With High-Dose Methotrexate With or Without Concomitant Infliximab Results From the ASPIRE Trial. 2006;54(3):702–10.59. Salaffi F. R eview Clinical disease activity assessments in rheumatoid arthritis R eview. 2013;347–60.60. Prevoo MLL, Hof MAVANT, Kuper HH, Leeuwen MAVAN. MODIFIED DISEASE ACTIVITY SCORES THAT INCLUDE TWENTY-EIGHT-JOINT COUNTS Development and Validation in a Prospective Longitudinal Study of Patients with Rheumatoid Arthritis. 1995;38(1):44–8.61. Singh H, Kumar H, Handa R, Talapatra P, Ray S, Gupta V. Use of Clinical Disease Activity Index Score for Assessment of Disease Activity in Rheumatoid Arthritis Patients : An Indian Experience. 2011;2011.62. Assessment MH, Health I, Questionnaire A. Measures of Functional Status and Quality of Life in Rheumatoid Arthritis. 2011;63(November):4–13.63. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the Health Assessment Questionnaire ( HAQ ) and the modified HAQ ( MHAQ ) in patients with rheumatoid arthritis. 2006;(454):454–864. Subramanian S. Remission in Rheumatoid arthritis: a reality in 2017. 2017;(January).65. Felson D. (2012). Defining remission in rheumatoid arthritis. Annals of the rheumatic diseases, 71 Suppl 2(0 2), i86–i88. https://doi.org/10.1136/annrheumdis66. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis : latest evidence and clinical considerations. 2017;249–62.67. Id YS, Yoshida K, Prince FHM, Frits ML, Cho K, Choe J, et al. Prevalence and predictors for sustained remission in rheumatoid arthritis. 2019;92:1–11.68. Yilmaz-oner S, Gazel U, Can M, Atagunduz P, Direskeneli H, Inanc N. Predictors and the optimal duration of sustained remission in rheumatoid arthritis. 2019;69. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. 2017;1–18.70. Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. 2019; 4:1–16.71. Peláez I, Cuervo F, Angarita I, Londo J, Giraldo R, Camilo J, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación prevalencia de enfermedad reumática en población colombiana mayor de 18 a nos. 2018;5(4):245–56.72. Montoya N, Rosselli D. Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia. 2011; 18:26–33.73. Kiely P, Williams R, Walsh D, Young A, Arthritis R, Eran N. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis : the ERAN cohort. 2009;(November 2008):57–60.74. Brian Tom , Characterization of disease course and remission in early seropositive rheumatoid arthritis: Results from the TACERA longitudinal cohort study RA-MAP Consortium, medRxiv 2020.03.08.2002814275. .Combe B. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. 2004;675–80.76. 1Boire G, Mph JEP, Hitchon C. 1. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study77. Thorne C, Bykerk V, Lazovskis J, Breton C, Hospital R. The Journal of Rheumatology Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists : A National , Multicenter , Retrospective Cohort. 2011;(April 2016).78. Boman A, Brink M, Lundquist A, Hansson M, Mathsson-alm L, Rönnelid J, et al. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis : a prospective longitudinal inception cohort study. 2019;1–10.79. Rydell E, Forslind K, Nilsson J-åke, Karlsson M, Åkesson KE, Jacobsson LTH, et al. Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis : a cohort study. 2021;1–13.80. Hmamouchi I, Combe B, Fautrel B, Rincheval N, Lukas C. validated indices in the early arthritis “ESPOIR ” cohort. Jt Bone Spine [Internet]. 2014; Available from: http://dx.doi.org/10.1016/j.jbspin.2014.02.00781. Lu B, Rho YH, Cui J, Christine K. Associations of Smoking and Alcohol Consumption With Disease Activity and Functional Status in Rheumatoid Arthritis2015;41(1):24–30.82. Paulus HE, Wiesner J, Bulpitt KENJ, Patnaik M, Law J, Park GS, et al. Autoantibodies in Early Seropositive Rheumatoid Arthritis , Before and During Disease Modifying Antirheumatic Drug Treatment. 2002;2513–20.83. Barahona-correa JE, Flórez-suárez J. Does healthcare regime affiliation influence the clinical outcomes of patients with rheumatoid arthritis ? 2020;84. Ma MHY, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PDW, et al. Remission in Early Rheumatoid Arthritis : Predicting Treatment Response. 2012;39(3). 85. Ma MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. 2020;1–12.86. Källmark H, Einarsson JT, Nilsson Å, Olofsson T, Saxne T, Geborek P. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy : A Swedish Nationwide Register Study. 2021;73(7):1135–44.87. Turk ,Kieran Murray, Yousef Alammari,1 Aine Gorman,1 Francis Young,1 Phil Gallagher, The effects of alcohol consumption and its associations with disease activity among 979 patients with inflammatory arthritis _ Enhanced Reader.pdf.88. Nissen MJ, Gabay C, Scherer A, Finckh A, Clinical S. The Effect of Alcohol on Radiographic Progression in Rheumatoid Arthritis. 2010;62(5):1265–72.89. Monteagudo-sa I, Kupper H. Clinical Remission and / or Minimal Disease Activity in Patients Receiving Adalimumab Treatment in a Multinational , Open-Label , Twelve-Week Study. 2008;59(1):32–41.90. Frisell T, Saevarsdottir S, Askling J. Does a family history of RA in fl uence the clinical presentation and treatment response in RA ? 2015;1–6.91. Radstake TRDJ, Barrera P, Albers JMC, Swinkels HL, Putte LBA Van De, Riel PLCM Van. Familial vs sporadic rheumatoid arthritis ( RA ). A prospective study in an early RA inception cohort. 2000;267–73.92. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, et al. Significance of Sex in Achieving Sustained Remission in the Consortium of Rheumatology Researchers of North America Cohort of Rheumatoid Arthritis Patients. 2012;64(12):1811–8.93. Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P, et al. Original article Sustained clinical remission in rheumatoid arthritis : prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. 2012;(November 2011):169–75.94. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. 2004;43(7):906–14.95. Anderson JJ, Wells G, Verhoeven AC, Felson DT. FACTORS PREDICTING RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS The Importance of Disease Duration. 2000;43(1):22–9.96. Ruiz-Esquide, V. Smoking Impact on Radiographic Progression in An Early Rheumatoid Arthritis Cohort, 201197. Saevarsdottir S, Wedre S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients With Early Rheumatoid Arthritis Who Smoke Are Less Likely to Respond to Treatment With Methotrexate and Tumor Necrosis Factor Inhibitors Observations From the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register Cohorts. 2011;63(1):26–36.98. Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis : current status and future studies. 2020;1–9.99. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–1099.EspecializadaFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombianaLICENSElicense.txtlicense.txttext/plain; charset=utf-83964https://repositorio.unal.edu.co/bitstream/unal/80045/1/license.txtcccfe52f796b7c63423298c2d3365fc6MD51ORIGINALFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana.pdfFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana.pdfTesis de Especialidad Médica en Reumatologíaapplication/pdf1039883https://repositorio.unal.edu.co/bitstream/unal/80045/2/Factores%20predictores%20de%20actividad%20cl%c3%adnica%20en%20paciente%20con%20artritis%20reumatoide%20temprana%20en%20una%20cohorte%20colombiana.pdf34ce8b1f816cb49e6f684e1b87accd36MD52THUMBNAILFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana.pdf.jpgFactores predictores de actividad clínica en paciente con artritis reumatoide temprana en una cohorte colombiana.pdf.jpgGenerated Thumbnailimage/jpeg4672https://repositorio.unal.edu.co/bitstream/unal/80045/3/Factores%20predictores%20de%20actividad%20cl%c3%adnica%20en%20paciente%20con%20artritis%20reumatoide%20temprana%20en%20una%20cohorte%20colombiana.pdf.jpg22df8cdcd40bdca11d7555aa4311b967MD53unal/80045oai:repositorio.unal.edu.co:unal/800452024-07-28 01:12:59.159Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

Publicaciones similares